Could a drug for rare blood disorder help pregnant women with severe preeclampsia?
NCT ID NCT06333652
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests ravulizumab (Ultomiris) in 14 pregnant individuals with severe preeclampsia or HELLP syndrome before 34 weeks of pregnancy. The drug aims to block part of the immune system that may drive these dangerous conditions. Researchers will measure blood markers and pregnancy duration to see if it helps.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ravulizumab (Ultomiris)
What this could lead to
If successful, this could point toward a new treatment option for severe preeclampsia and HELLP syndrome, potentially improving outcomes for pregnant individuals.
What could go wrong
This is a very small early-phase trial with only 14 participants, so results may not apply broadly. The drug may not improve pregnancy outcomes or could have unforeseen risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREECLAMPSIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
Locations
-
Mayo Clinic Minnesota
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••